...
首页> 外文期刊>Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology >Progesterone for preparation of the endometrium for frozen-thawed blastocyst transfer in vitro fertilization cycles: a prospective study on patients' opinions on a new subcutaneous formulation
【24h】

Progesterone for preparation of the endometrium for frozen-thawed blastocyst transfer in vitro fertilization cycles: a prospective study on patients' opinions on a new subcutaneous formulation

机译:用于制备用于冷冻胚泡转移的子宫内膜的孕激素,体外施肥循环:对新皮下制剂的患者观点的前瞻性研究

获取原文
获取原文并翻译 | 示例

摘要

We aimed to evaluate patients' perspectives on a progesterone subcutaneous formulation for endometrial preparation for frozen-thawed blastocyst transfer. In this prospective study, women with at least one experience with vaginal progesterone, undergone endometrial preparation with oral estradiol valerate and daily subcutaneous progesterone administered from the fifth day before the transfer until the day of the beta-hCG test. Patients completed three questionnaires, at enrollment (Q1), for gathering information on the experience with vaginal treatment and expectations about the subcutaneous route and then at the time of the transfer (Q2) and eight days later (Q3). Main outcome measures were patients' opinions on comfort, ease of use, convenience, overall satisfaction, level of anxiety and pain associated with the administration of subcutaneous progesterone in comparison with their previous experience. Sixty-nine women completed the questionnaires. All vaginal versus subcutaneous comparisons were significantly in favor of the subcutaneous route. When comparing patients' expectations at Q1 with patients' opinions at Q2 and Q3, all evaluations, except for one, demonstrated that the patient's positive expectation was confirmed after 5 and 13 days of treatment. In conclusion, in women with previous experience with vaginal progesterone, the subcutaneous route was associated with significantly increased acceptance.
机译:我们旨在评估患者对孕酮皮下制剂的患者的透视,用于冷冻囊肿转移的子宫内膜制剂。在这项前瞻性研究中,患有至少一种具有阴道孕酮的经验的妇女,内膜制剂具有口服雌二醇律和日常皮下孕酮,从第五天施用,直至β-HCG试验。患者在注册(Q1)时完成了三项问卷,用于收集关于阴道治疗和对皮下途径的预期经验的信息,然后在转移时(Q2)和八天后(Q3)。主要的结果措施是患者对舒适性,便于,方便,总体满意度,与对皮下孕酮的焦虑和疼痛相比的舒适性,方便,总体满意度,疼痛程度的患者的意见。六十九名妇女完成了问卷。所有阴道与皮下比较都有利于皮下途径。在将患者在Q2和Q3的患者的意见中与患者的观点进行比较时,除了一个外,所有评估都证明了患者的积极期望在治疗5和13天后确认。总之,在患有前期经验的女性对阴道孕酮的经验中,皮下途径与显着增加的接受程度有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号